Azeliragon
Azeliragon is a potent RAGE (the receptor for advanced glycation end products) inhibitor. It has been evaluated for potential treatment for patients with mild-to-moderate Alzheimer's disease (AD). Azeliragon decreases brain amyloid in mice and improves their performance on behavior tests. Azeliragon is a promising agent for for Alzheimer's disease and cerebral amyloid angiopathy.
Product Specifications
Shipping Conditions
gel pack
Storage Conditions
-20°C
Shelf Life
36 months
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1030956-01 0.02 mg (E-Coli)
Recombinant Brucella canis Sulfate adenylyltransferase subunit 2 (cysD)
Sign In for Pricing
View Details 
MBS1030956-02 0.02 mg (Yeast)
Recombinant Brucella canis Sulfate adenylyltransferase subunit 2 (cysD)
Sign In for Pricing
View Details MBS1030956-03 0.1 mg (E-Coli)
Recombinant Brucella canis Sulfate adenylyltransferase subunit 2 (cysD)
Sign In for Pricing
View Details 
MBS1030956-04 0.1 mg (Yeast)
Recombinant Brucella canis Sulfate adenylyltransferase subunit 2 (cysD)
Sign In for Pricing
View Details MBS1030956-05 0.02 mg (Baculovirus)
Recombinant Brucella canis Sulfate adenylyltransferase subunit 2 (cysD)
Sign In for Pricing
View Details MBS1030956-06 0.02 mg (Mammalian-Cell)
Recombinant Brucella canis Sulfate adenylyltransferase subunit 2 (cysD)
Sign In for Pricing
View Details